Citations

Showing 10 of 108104 citations.

Abstract P179: A Text Processing Tool To Identify And Characterize Carotid Artery Stenosis In Radiology Reports
Elsekaily, Omar, Alhalabi, Lubna, Kullo, Iftikhar, Saadatagah, Seyedmohammad

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | May 2, 2022 | Volume: 41 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.41.suppl_1.p179 Get It

Introduction: We aimed to identify and characterize carotid artery stenosis (CAS), defined as ≥40% stenosis in the internal carotid artery (ICA) or the common carotid artery (CCA), among participants of the Mayo Vascular Disease Biorepository (VDB, n = 11,814). Hypothesis: A string-based text processing (TP) tool coded in R can analyze radiology text reports to ascertain and characterize CAS. Methods: After importing a radiology report into R, it was segmented for analysis and each segment was tested for 22 unique features. The TP tool was able to i) identify stenosis in the ICA or the CCA while excluding stenosis of vertebral arteries, subclavian arteries, or external carotid arteries, ii) recognize both quantitative and qualitative descriptions of CAS, iii) interpret numerical expressions by considering the surrounding text, iv) detect negations, and v) ascertain previous revascularization procedures if mentioned in the text. We manually ascertained CAS and characterized it in 800 randomly selected radiology reports to assess the performance of the TP tool in terms of precision, recall, and F-score. Results: We retrieved 21,651 imaging reports for 6,342 unique patients including 20,461 ultrasonography reports, 812 magnetic resonance imaging reports, 357 computed tomography scan reports, and 21interventional radiology reports. The performance of TP is outlined in Table 1 . Conclusion: We demonstrate that a string-based TP tool coded in R is efficient and accurate in identifying and characterizing CAS from carotid radiology reports. The tool does not require natural language processing and could be used in a wide range of settings for genetic and biomarker studies.
Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma
Zhang, Bo , Peng, Hui , Zhou, Mi , Bao, Lei , Wang, Chenliang , Cai, Feng , Zhang, Hongxia , Wang, Jennifer E. , Niu, Yan-Ling, Chen, Yan , Hatanpaa, Kimmo J. , Copland, John A. , Wang, Yingfei , Luo, Weibo , Wang, Yijie , DeBerardinis, Ralph J.

Mayo Clinic

Cancer Research | May 2, 2022 | Volume: 82 | Issue: 13 | Pages: 2388-2402

10.1158/0008-5472.can-21-3868 | PMID 35499760 Get It

Abstract Branched-chain amino acid transaminase 1 (BCAT1) is upregulated selectively in human isocitrate dehydrogenase (IDH) wildtype (WT) but not mutant glioblastoma multiforme (GBM) and promotes IDHWT GBM growth. Through a metabolic synthetic lethal screen, we report here that α-ketoglutarate (AKG) kills IDHWT GBM cells when BCAT1 protein is lost, which is reversed by reexpression of BCAT1 or supplementation with branched-chain α-ketoacids (BCKA), downstream metabolic products of BCAT1. In patient-derived IDHWT GBM tumors in vitro and in vivo, cotreatment of BCAT1 inhibitor gabapentin and AKG resulted in synthetic lethality. However, AKG failed to evoke a synthetic lethal effect with loss of BCAT2, BCKDHA, or GPT2 in IDHWT GBM cells. Mechanistically, loss of BCAT1 increased the NAD+/NADH ratio but impaired oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis. These metabolic alterations were synergistically augmented by AKG treatment, thereby causing mitochondrial dysfunction and depletion of cellular building blocks, including ATP, nucleotides, and proteins. Partial restoration of ATP, nucleotides, proteins, and mTORC1 activity by BCKA supplementation prevented IDHWT GBM cell death conferred by the combination of BCAT1 loss and AKG. These findings define a targetable metabolic vulnerability in the most common subset of GBM that is currently incurable. Significance: Metabolic synthetic lethal screening in IDHWT glioblastoma defines a vulnerability to ΑΚG following BCAT1 loss, uncovering a therapeutic strategy to improve glioblastoma treatment. See related commentary by Meurs and Nagrath, p. 2354
Drug Interactions Affecting Antiarrhythmic Drug Use
Mar, Philip L. , Horbal, Piotr J. , Chung, Mina K. , Dukes, Jonathan W., Ezekowitz, Michael D. , Lakkireddy, Dhanunjaya , Miletello, Mike, Noseworthy, Peter A. , Reiffel, James A. , Horbal, Piotr , Ezekowitz, Michael , Lip, Gregory Y H , Miletello, Mike , Noseworthy, Peter A , Reiffel, James A , Tisdale, James E , Olshansky, Brian , Gopinathannair, Rakesh , Dukes, Jonathan W., Olshansky, Brian , Gopinathannair, Rakesh

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 2, 2022 | Volume: 15 | Issue: 5 | Pages: No page available

10.1161/circep.121.007955 | PMID 35491871 Get It

Antiarrhythmic drugs (AAD) play an important role in the management of arrhythmias. Drug interactions involving AAD are common in clinical practice. As AADs have a narrow therapeutic window, both pharmacokinetic as well as pharmacodynamic interactions involving AAD can result in serious adverse drug reactions ranging from arrhythmia recurrence, failure of device-based therapy, and heart failure, to death. Pharmacokinetic drug interactions frequently involve the inhibition of key metabolic pathways, resulting in accumulation of a substrate drug. Additionally, over the past 2 decades, the P-gp (permeability glycoprotein) has been increasingly cited as a significant source of drug interactions. Pharmacodynamic drug interactions involving AADs commonly involve additive QT prolongation. Amiodarone, quinidine, and dofetilide are AADs with numerous and clinically significant drug interactions. Recent studies have also demonstrated increased morbidity and mortality with the use of digoxin and other AAD which interact with P-gp. QT prolongation is an important pharmacodynamic interaction involving mainly Vaughan-Williams class III AAD as many commonly used drug classes, such as macrolide antibiotics, fluoroquinolone antibiotics, antipsychotics, and antiemetics prolong the QT interval. Whenever possible, serious drug-drug interactions involving AAD should be avoided. If unavoidable, patients will require closer monitoring and the concomitant use of interacting agents should be minimized. Increasing awareness of drug interactions among clinicians will significantly improve patient safety for patients with arrhythmias.
End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma
Dixon, Jesse G. , Dimier, Natalie , Nielsen, Tina, Zheng, Jamie , Marcus, Robert, Evens, Andrew M. , Blum, Kristie A. , Shi, Qian , Blum, Kristie A , Shi, Qian , Evens, Andrew M , Dixon, Jesse G , Morschhauser, Franck , Federico, Massimo

Mayo Clinic

British Journal of Haematology | May 2, 2022 | Volume: 198 | Issue: 2 | Pages: 333-337

10.1111/bjh.18217 | PMID 35491747 Get It

SummaryProgression‐free survival (PFS) has been the regulatory primary end‐point for recent phase III trials in first‐line follicular lymphoma (FL), but requires prolonged follow‐up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end‐point for PFS. Our objective was to further evaluate surrogacy of CR measured by [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at the end of induction (EoI). Individual patient data were analysed from 1505 patients from five randomized trials. Trial‐level surrogacy examining the association between treatment effects on EoI‐PET‐CR and PFS was evaluated using linear regression () and bivariate Copula () models. Although EoI‐PET‐CR strongly predicted PFS at a prognostic level, the trial‐level assessment did not show strong correlation (, confidence interval [CI]: 0.20–0.88; , CI: 0.0–0.82). The high uncertainty in estimation was possibly due to the small number of trials and the population of patients with available PET data. Maintenance therapy affecting PFS beyond induction treatment, but not EoI‐PET‐CR end‐point, may have distorted the association between treatment effects. However, there will probably be a number of additional trials approaching completion with available PET response data. Refined evaluation of PET‐CR based surrogate end‐points is still warranted.
Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock
Jentzer, Jacob C. , Patel, Parag C. , Barsness, Gregory W. , Holmes, David R. , Kirchhof, Paulus , Westermann, Dirk , Schrage, Benedikt , Barsness, Gregory W , Holmes, David R , Kirchhof, Paulus , Westermann, Dirk , Jentzer, Jacob C , Schrage, Benedikt , Kashani, Kianoush , Blankenberg, Stefan

Mayo Clinic

Journal of the American Heart Association | May 2, 2022 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/jaha.121.024932 | PMID 35491996 Get It

Background Lactic acidosis is associated with mortality in patients with cardiogenic shock (CS). Elevated lactate levels and systemic acidemia (low blood pH) have both been proposed as drivers of death. We, therefore, analyzed the association of both high lactate concentrations and low blood pH with 30‐day mortality in patients with CS. Methods and Results This was a 2‐center historical cohort study of unselected patients with CS with available data for admission lactate level or blood pH. CS severity was graded using the Society for Cardiovascular Angiography and Intervention (SCAI) shock classification. All‐cause survival at 30 days was analyzed using Kaplan‐Meier curves and Cox proportional‐hazards analysis. There were 1814 patients with CS (mean age, 67.3 years; 68.5% men); 51.8% had myocardial infarction and 53.0% had cardiac arrest. The distribution of SCAI shock stages was B, 10.8%; C, 30.7%; D, 38.1%; and E, 18.7%. In both cohorts, higher lactate or lower pH predicted a higher risk of adjusted 30‐day mortality. Patients with a lactate ≥5 mmol/L or pH <7.2 were at increased risk of adjusted 30‐day mortality; patients with both lactate ≥5 mmol/L and pH <7.2 had the highest risk of adjusted 30‐day mortality. Patients in SCAI shock stages C, D, and E had higher 30‐day mortality in each SCAI shock stage if they had lactate ≥5 mmol/L or pH <7.2, particularly if they met both criteria. Conclusions Higher lactate and lower pH predict mortality in patients with cardiogenic shock beyond standard measures of shock severity. Severe lactic acidosis may serve as a risk modifier for the SCAI shock classification. Definitions of refractory or hemometabolic shock should include high lactate levels and low blood pH.
Manifestations of radiation toxicity in the head, neck, and spine: An image-based review
Benson, John C. , Kim, Dong K, Nagelschneider, Alex A. , Madhavan, Ajay A. , Johnson, Derek R. , Benson, John , DeLone, David R. , Diehn, Felix E. , Madhavan, Ajay A , Johnson, Derek R , Carr, Carrie M. , Daniel, J.

Mayo Clinic

The Neuroradiology Journal | May 1, 2022 | Volume: 35 | Issue: 4 | Pages: 427-436

10.1177/19714009221096824 | PMID 35499087 Get It

Background and purpose Radiation therapy is an important component of treatment in patients with malignancies of the head, neck, and spine. However, radiation to these regions has well-known potential side effects, many of which can be encountered on imaging. In this manuscript, we review selected radiographic manifestations of therapeutic radiation to the head, neck, and spine that may be encountered in the practice of radiology. Methods We conducted an extensive literature review of known complications of radiation therapy in the head, neck, and spine. We excluded intracranial and pulmonary radiation effects from our search. We selected complications that had salient, recognizable imaging findings. We searched our imaging database for illustrative examples of these complications. Results Based on our initial literature search and imaging database review, we selected cases of radiation-induced tumors, radiation tissue necrosis (osteoradionecrosis and soft tissue necrosis), carotid stenosis and blowout secondary to radiation, enlarging thyroglossal duct cysts, radiation myelopathy, and radiation-induced vertebral compression fractures. Conclusions We describe the clinical and imaging features of selected sequelae of radiation therapy to the head, neck, and spine, with a focus on those with characteristic imaging findings that can be instrumental in helping to make the diagnosis. Knowledge of these entities and their imaging findings is crucial for accurate diagnosis. Not only do radiologists play a key role in early detection of these entities, but many of these entities can be misinterpreted if one is not familiar with them.
International consensus on diagnosis and management of Dravet syndrome
Wirrell, Elaine , Hood, Veronica , Knupp, Kelly G. , Meskis, Mary Anne , Nabbout, Rima , Scheffer, Ingrid E. , Wilmshurst, Jo M. , Sullivan, Joseph , Wirrell, Elaine C , Wilmshurst, Jo M , Scheffer, Ingrid E , Knupp, Kelly G

Mayo Clinic

Epilepsia | May 1, 2022 | Volume: 63 | Issue: 7 | Pages: 1761-1777

10.1111/epi.17274 | PMID 35490361 Get It

Abstract Objective This study was undertaken to gain consensus from experienced physicians and caregivers regarding optimal diagnosis and management of Dravet syndrome (DS), in the context of recently approved, DS‐specific therapies and emerging disease‐modifying treatments. Methods A core working group was convened consisting of six physicians with recognized expertise in DS and two representatives of the Dravet Syndrome Foundation. This core group summarized the current literature (focused on clinical presentation, comorbidities, maintenance and rescue therapies, and evolving disease‐modifying therapies) and nominated the 31‐member expert panel (ensuring international representation), which participated in two rounds of a Delphi process to gain consensus on diagnosis and management of DS. Results There was strong consensus that infants 2–15 months old, presenting with either a first prolonged hemiclonic seizure or first convulsive status epilepticus with fever or following vaccination, in the absence of another cause, should undergo genetic testing for DS. Panelists agreed on evolution of specific comorbidities with time, but less agreement was achieved on optimal management. There was also agreement on appropriate first‐ to third‐line maintenance therapies, which included the newly approved agents. Whereas there was agreement for recommendation of disease‐modifying therapies, if they are proven safe and efficacious for seizures and/or reduction of comorbidities, there was less consensus for when these should be started, with caregivers being more conservative than physicians. Significance This International DS Consensus, informed by both experienced global caregiver and physician voices, provides a strong overview of the impact of DS, therapeutic goals and optimal management strategies incorporating the recent therapeutic advances in DS, and evolving disease‐modifying therapies.
Turnbull–Cutait abdominoperineal pull‐through operation: The Cleveland Clinic experience in the 21st century
Lavryk, Olga , Bandi, Bethany, Shawki, Sherief , Floruta, Crina, Jia, Xue , Valente, Michael , Hull, Tracy L. , Steele, Scott R.

Mayo Clinic

Colorectal Disease | May 1, 2022 | Volume: 24 | Issue: 10 | Pages: 1184-1191

10.1111/codi.16163 | PMID 35490348 Get It

AbstractAimThe Turnbull–Cutait pull‐through procedure (TCO) restores intestinal continuity in the setting of chronic pelvic sepsis, colorectal anastomotic leak, complex pelvic fistulas and technical challenges related to complicated rectal cancer. The aim of this study was to evaluate the outcomes of the TCO for salvaging complex pelvic conditions and to compare it to hand‐sewn immediate coloanal anastomosis (CAA).MethodsThis is a retrospective single‐institution study where we searched a prospectively maintained database to identify patients who underwent the TCO. Patient demographics, operative indications and outcomes were analysed. TCO success was defined as maintenance of intestinal continuity and being stoma‐free. Kaplan–Meier analysis was employed for stoma‐free survival analysis.ResultsA total of 81 patients with TCO and 129 patients with CAA were included. The TCO success rate was 69% at a median of 1.4 years’ follow‐up with 25 (31%) patients ending up with a permanent stoma compared to 22 (17%) in the CAA group with a median follow‐up of 4 years (P = 0.03). The Kaplan–Meier cumulative incidence of TCO success at 1, 3 and 5 years was 79%, 60% and 51%, respectively, compared to 91%, 81% and 73% after CAA.ConclusionThe TCO has a high success rate for patients with complex pelvic conditions who may be facing a permanent stoma as their only option.
Liner malseating is rare with two modular dual-mobility designs
Wooster, Benjamin M., Trousdale, Robert T. , Siljander, Matthew P , Gausden, Elizabeth B. , Karczewski, Daniel , Sierra, Rafael J. , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | May 1, 2022 | Volume: 104-B | Issue: 5 | Pages: 598-603

10.1302/0301-620x.104b5.bjj-2021-1734.r1 | PMID 35491581 Get It

Aims The aim of this study was to evaluate the incidence of liner malseating in two commonly used dual-mobility (DM) designs. Secondary aims included determining the risk of dislocation, survival, and clinical outcomes. Methods We retrospectively identified 256 primary total hip arthroplasties (THAs) that included a DM component (144 Stryker MDM and 112 Zimmer-Biomet G7) in 233 patients, performed between January 2012 and December 2019. Postoperative radiographs were reviewed independently for malseating of the liner by five reviewers. The mean age of the patients at the time of THA was 66 years (18 to 93), 166 (65%) were female, and the mean BMI was 30 kg/m2 (17 to 57). The mean follow-up was 3.5 years (2.0 to 9.2). Results Three liners (1.2%) were malseated, including two MDMs (1.4%) and one G7 (0.9%). No clinical consequence was identified from malseating. The five-year survival free of dislocation was 97.1%, including two DM and one intraprosthetic dislocation. The five-year survival free of revision was 95.4%, with seven revisions. The mean Harris Hip Scores increased from 46 (24 to 69) preoperatively to 81 (40 to 100) at two years postoperatively (p < 0.001). Conclusion The incidence of DM liner malseating after primary THA was low, with no known clinical consequences at mid-term follow-up. Malseating is not exclusive of design, and these findings emphasize the importance of careful evaluation of the liner after impaction to avoid this complication. Cite this article: Bone Joint J 2022;104-B(5):598–603.
Standardized Change-of-Shift Handoff: Nurses’ Perspectives and Implications for Evidence-Based Practice
Rhudy, Lori M. , Johnson, Maren, Krecke, Catherine, Keigley, Danielle S., Kraft, Sarah , Maxson, Pamela M., McGill, Sharon M., Warfield, Karen T. , Johnson, Maren R, Krecke, Catherine A, Kraft, Sarah J

Mayo Clinic

American Journal of Critical Care | May 1, 2022 | Volume: 31 | Issue: 3 | Pages: 181-188

10.4037/ajcc2022629 | PMID 35466352 Get It

Background Nursing handoff is a communication activity with a high risk for loss or omission of information. Efforts to improve handoffs include standardization of the processes and content of handoff communications. Objectives To examine nurses’ perspectives on the structure and organization of change-of-shift handoffs. Methods A qualitative descriptive approach was used to conduct a secondary analysis of focus group data. Thirty-four nurses from 4 critical care units participated in focus groups. Results Three themes emerged: handoff elements are defined by practice and culture; a clear, consistent, identified structure supports handoff; and personal preferences can disrupt handoff. Conclusions A standardized approach to handoff based on unit and organizational needs will be more successful than a broad mandate of content and organization. Individual preference is prevalent and strongly influences the information conveyed and the structure of handoff communication.